RNS Number : 8443J
  Lombard Medical Technologies PLC
  10 December 2008
   

    Press Information

    Lombard Medical Technologies PLC
    ("Lombard Medical" or "the Company")

    EndoRefix* Trial Suspended


    London, UK, 10 December 2008 - Lombard Medical Technologies PLC ("Lombard Medical" or "the Company"), the specialist medical device
company, announces that in order to save costs enrolment of the EndoRefix* US trial has been put on hold.

    The study has enrolled 60 patients to date out of a total requirement of 95 patients. The decision to put the study on hold was taken in
order to prolong the Company's limited cash resources whilst it secures further funds.

    The Company remains in discussions with potential investors and expects to update the market on developments in due course.

    Enquiries:

 Lombard Medical Technologies PLC           Tel: 01235 750 800
 Simon Neathercoat, Non-executive Chairman
 Brian Howlett, Chief Executive Officer
 Tim Hall, Finance Director

 Financial Dynamics                         Tel: 020 7831 3113
 David Yates / Susan Quigley

 Nomura Code                                Tel: 020 7776 1200
 Juliet Thompson / Richard Potts

    Notes to editors
    About Lombard Medical
    Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment
of vascular disease. The Company's lead product, Aorfix*, is an endovascular stent graft for the treatment of abdominal aortic aneurysms
(AAAs), a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Approximately 1.7 million people have AAAs
in the US where it is the 13th largest cause of death. The market for endovascular stent grafts for the treatment of AAA is currently worth
over $600 million and is expected to grow to around a $1 billion by 2010. Aorfix* is currently being commercialised in the EU, with a
pivotal clinical trial ongoing in the USA.  

    The Company's Polymer Coatings Division has developed a novel hydrophilic surface treatment to reduce friction on catheters called
GlideMax*, which is available for licensing, and is using its polymer coating technology in a number of research collaborations developing
novel products for the $5 billion drug-eluting stent market.

    The Company headquartered in Oxfordshire, with operations in Yorkshire, Ayrshire and Boston, USA.
    Further background on the Company can be found at www.lombardmedical.com. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCDBBDDBDGGGIC
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.